Case report: life-threatening hypoglycaemia associated with sulfadoxine-pyrimethamine, a commonly used antimalarial drug.
Due to chloroquine resistance, several African countries have changed their first-line malaria treatment to sulfadoxine-pyrimethamine (SP). In this report, we present a case of hypoglycaemic coma associated with SP, an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of SP increases.
Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. rfairhurst@niaid.nih.gov
R M
RM
Fairhurst
B
B
Sadou
A
A
Guindo
D A
DA
Diallo
O K
OK
Doumbo
T E
TE
Wellems
D000962:Antimalarials / Q000009:adverse effects*; D004338:Drug Combinations; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced*; D007223:Infant; D016778:Malaria, Falciparum / Q000188:drug therapy*; D008297:Male; D011739:Pyrimethamine / Q000009:adverse effects*; D013413:Sulfadoxine / Q000009:adverse effects*
D000962:Antimalarials; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D011739:Pyrimethamine